Back to Search
Start Over
Statin safety and associated adverse events: a scientific statement from the American Heart Association
- Publication Year :
- 2019
- Publisher :
- American Heart Association, 2019.
-
Abstract
- One in 4 Americans >40 years of age takes a statin to reduce the risk of myocardial infarction, ischemic stroke, and other complications of atherosclerotic disease. The most effective statins produce a mean reduction in low-density lipoprotein cholesterol of 55% to 60% at the maximum dosage, and 6 of the 7 marketed statins are available in generic form, which makes them affordable for most patients. Primarily using data from randomized controlled trials, supplemented with observational data where necessary, this scientific statement provides a comprehensive review of statin safety and tolerability. The review covers the general patient population, as well as demographic subgroups, including the elderly, children, pregnant women, East Asians, and patients with specific conditions such as chronic disease of the kidney and liver, human immunodeficiency viral infection, and organ transplants. The risk of statin-induced serious muscle injury, including rhabdomyolysis, is
- Subjects :
- medicine.medical_specialty
Statin
medicine.drug_class
Population
030204 cardiovascular system & hematology
Kidney
Rhabdomyolysis
law.invention
03 medical and health sciences
0302 clinical medicine
Muscular Diseases
Randomized controlled trial
law
Internal medicine
Diabetes mellitus
Diabetes Mellitus
medicine
Humans
Drug Interactions
cardiovascular diseases
030212 general & internal medicine
Myocardial infarction
education
Stroke
Cerebral Hemorrhage
Randomized Controlled Trials as Topic
education.field_of_study
business.industry
American Heart Association
medicine.disease
United States
Liver
Tolerability
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cardiology and Cardiovascular Medicine
business
Subjects
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....ae3e3feb0b8d9b97d04b0388ee0fcc85